Use access key #2 to skip to page content.
$69.54 0.16 (0.23%)
5/9/2008 4:00 PM

Genzyme Corp (GENZ)

CAPS Rating:
*****

A biotechnology company dedicated to making an impact on the lives of people with serious diseases. Its product and service portfolio is focused on rare disorders, renal diseases, orthopaedics, organ transplant, and diagnostic and predictive testing.

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other players to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

You aren't currently rating GENZ

Add Stock to Watchlist

What the Community Thinks Add a widget featuring this stock to your blog!

Total Players

314 Outperforms
18 Underperforms
 

All-Stars

101 Outperforms
5 Underperforms
 

Wall Street

11 Outperforms
0 Underperforms
 

Players bullish on GENZ are also bullish on:

Players bearish on GENZ are also bearish on:

Ticker Tags

Cambridge (4), S&P 500 (484), Massachusetts (15), Nasdaq 100 (99), Large Cap (467), Biotechnology (291)
Suggest a tag

Genzyme Corp At A Glance

Current Price: $69.54
Last Trade Time: 5/9/2008 4:00 PM
Open: $0.00
Previous Close: $69.38
Daily Range: $68.38 - $69.84
52-Week Range: $58.71 - $82.08
Volume: 1,928,605
Market Cap: $18.52B
P/E Ratio: 31.54
Compare Our Special Broker Offers!

Stock Trends

GENZ VS S&P 500 (SPY)

GENZ 12 month chart vs. S&P

News & Discussion Boards

Top Bull Pitch

Recs

2

Genzyme Corp (GENZ)

Avatar madiasha (< 20) Submitted: 5/03/07 1:09 PM

GENZ looks too much like a takeover target because of product and pipeline.Value is much more than present capitalization.

Replies: 0 | Reply | Permalink

Top Bear Pitch

Recs

1

Genzyme Corp (GENZ)

Avatar StockTalking (53.17) Submitted: 8/16/07 12:03 PM

out for cash.


http://mystockmistakes.blogspot.com/

Replies: 0 | Reply | Permalink

CAPS Players

picks per page. CHANGE

Results 1 - 5 of 33 :   1 2 3 4 5 Next »

Recs

0

 (GENZ)

Avatar ChavoTX (44.15) Submitted: 4/24/08 5:37 PM : Outperform Start Price: $72.69 GENZ Score: -3.94

Great potential!

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (GENZ)

Avatar ResearchLover (95.00) Submitted: 4/23/08 3:42 PM : Outperform Start Price: $73.12 GENZ Score: -5.64

I like the chart with rising MAs, earnings just announced showing growth, and the forward PE of 20 at this price. Plus they could spin off or sell off any one of their six segments if business development at another company justifies a synergistic valuation.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (GENZ)

Avatar GS751 (89.54) Submitted: 4/15/08 11:29 AM : Outperform Start Price: $72.14 GENZ Score: -8.39

A large cap play that I stole from Florida Builder. Already priced as if the R &D is gonna come through. I'll be on the betting line.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (GENZ)

Avatar Budsworth (73.10) Submitted: 4/05/08 5:29 AM : Outperform Start Price: $75.95 GENZ Score: -9.16

With the most recent resolution over manufacturing issues of MYOZYME enzyme replacement therapy for Pomp disease: should help gain favor with the FDA.
They will be announcing mid stage data for the drug CLOLAR at the American Society for Clinical Oncology Conference. It is a treatment for childhood leukemia. They feel they have some very positive news to reveal. Also they will be announcing data for a treatment for oral Gaucher disease to be released in mid 2008.
They are very excited about this most recent positive news.
A well managed Bio-company with some real positive news. I'll go with them on this!

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (GENZ)

Avatar jchallis (61.29) Submitted: 3/23/08 3:19 PM : Outperform Start Price: $71.97 GENZ Score: -7.57

This company has a great competitive advantage -- they produce life-saving drugs for relatively rare diseases. Being low volume, they can continue to hold their niche against big players. Having been in the game for over 25 years, they can hold their own against newcomers. You gotta love that drug pipeline...

Report this Post Replies: 0 | Reply | Permalink

Results 1 - 5 of 33 :   1 2 3 4 5 Next »

Wall Street

Results 1 - 11 of 11  

picks per page. CHANGE Expand All Pitches

Top
Pick
Player NamePlayer RatingStart
Date
CallTime FrameStart
Price
Stock
Gain
S&P
Gain
ScorePitch
TrackLazardCapit < 20 04/04/08 Outperform NS $75.09-7.39%+0.81%-8.20
TrackZacks 94.64 12/17/07 Outperform 3M $73.53-5.43%-4.25%-1.17 Toggle the visibility of 60-Second Pitch and replies
TrackWachovia 78.55 10/11/07 Outperform NS $70.00-0.66%-11.49%+10.83
TrackEdwardOwens 73.59 09/30/07 Outperform NS $61.96+12.23%-8.97%+21.20 Toggle the visibility of 60-Second Pitch and replies
TrackEveillard 84.84 09/30/07 Outperform NS $61.96+12.23%-8.97%+21.20 Toggle the visibility of 60-Second Pitch and replies
TrackFortisBank 98.19 07/09/07 Outperform NS $61.08+13.85%-9.30%+23.16
TrackLehmanBros 86.07 06/26/07 Outperform NS $64.25+8.23%-7.53%+15.76
TrackMatrix 87.19 03/15/07 Outperform NS $60.40+15.13%-0.05%+15.18
TrackStifel 87.42 01/31/07 Outperform NS $65.33+6.44%-2.62%+9.06
TrackRWBaird 27.50 01/04/07 Outperform NS $63.59+9.36%-1.65%+11.01
TrackAGEdwards 88.60 08/30/06 Outperform NS $66.46+4.63%+6.14%-1.50
TrackJimCramer 81.10 05/25/06 Outperform 3W $58.50+18.87%+8.19%+10.68

Results 1 - 11 of 11  

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.

Featured Broker Partners